SCHEMBL309351

SCHEMBL309351

CC(=O)OCC(COC(C)=O)(COC(C)=O)COC(C)=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.50
LMNA P02545 1/20 0.50
HSD17B10 Q99714 1/20 0.50
CHRM5 P08912 2/20 0.40
CHRM1 P11229 2/20 0.40
CHRM3 P20309 2/20 0.40
TSHR P16473 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
PGR P06401 1/20 0.40
CHRM2 P08172 1/20 0.40
CHRM4 P08173 1/20 0.40
HTR1A P08908 1/20 0.40
CHRNB2 P17787 1/20 0.40
TBXA2R P21731 1/20 0.40
CHRNB4 P30926 1/20 0.40
CHRNA3 P32297 1/20 0.40
CHRNA7 P36544 1/20 0.40
CHRNA4 P43681 1/20 0.40
CHRNA10 Q9GZZ6 1/20 0.40
CHRNA9 Q9UGM1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL813641 0.92 ALDH1A1 (0.43) ALDH1A1LMNAHSD17B10CHRM5CHRM1
SCHEMBL12384153 0.89 ALDH1A1 (0.42) ALDH1A1LMNAHSD17B10CHRM5CHRM1
SCHEMBL10584206 0.86 ALDH1A1 (0.46) ALDH1A1LMNAHSD17B10CHRM5CHRM1
SCHEMBL832777 0.86 ALDH1A1 (0.52) ALDH1A1LMNAHSD17B10CHRM5CHRM1
SCHEMBL725624 0.86 ALDH1A1 (0.46) ALDH1A1LMNAHSD17B10CHRM5CHRM1
SCHEMBL540580 0.86 ALDH1A1 (0.50) ALDH1A1LMNAHSD17B10CHRM5CHRM1
SCHEMBL16546891 0.86 ALDH1A1 (0.50) ALDH1A1LMNAHSD17B10CHRM5CHRM1
SCHEMBL11588666 0.85 ALDH1A1 (0.44) ALDH1A1LMNAHSD17B10CHRM5CHRM1
SCHEMBL7038816 0.84 ALDH1A1 (0.42) ALDH1A1LMNAHSD17B10CHRM5CHRM1
SCHEMBL19197234 0.84 ALDH1A1 (0.42) ALDH1A1LMNAHSD17B10CHRM5CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1035 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120118420-A Ultraviolet-resistant fluoropolymer film and application thereof 浙江省化工研究院有限公司 2025-06-10 CN claimed
CN-120083913-A Drag reducing composition, preparation method thereof and pipeline drag reducer 广昌达新材料技术服务(深圳)股份有限公司 2025-06-03 CN claimed
CN-116426058-B Polyethylene casting film and preparation method thereof 天津市中泰创展科技有限公司 2025-02-25 CN claimed
CN-114203337-B High-resilience solar cell front silver paste and preparation method thereof 江苏聚盈新材料科技有限公司 2024-10-25 CN claimed
CN-118139925-A Polyvinyl acetal resin composition, inorganic fine particle dispersion slurry composition, and laminated ceramic capacitor 积水化学工业株式会社 2024-06-04 CN claimed
CN-118086986-A High-coverage electroplated copper additive composition for printed circuit board 广东利尔化学有限公司 2024-05-28 CN claimed
WO-2023189847-A1 POLYVINYL ACETAL RESIN COMPOSITION, INORGANIC-PARTICLE-DISPERSED SLURRY COMPOSITION, AND MULTILAYER CERAMIC CAPACITOR 積水化学工業株式会社 2023-10-05 WO claimed
CN-116426058-A Polyethylene casting film and preparation method thereof 天津市中泰创展科技有限公司 2023-07-14 CN claimed
US-20230218605-A1 AMORPHOUS SOLID DISPERSION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE ABIVAX (FR) 2023-07-13 US claimed
CN-112516085-B Tilmicosin solution and preparation method and use method thereof 佛山市正典生物技术有限公司 2023-04-07 CN claimed
EP-1967181-A1 Pharmaceutical formulation comprising a CB1-Receptor compound in a solid solution and/or solid dispersion Laboratorios del Dr. Esteve S.A. (ES) 2008-09-10 EP claimed
US-20070249692-A1 INHIBITORS OF CRYSTALLIZATION IN A SOLID DISPERSION ABBVIE INC. 2007-10-25 US claimed
WO-2007030375-A2 LYSOSOMAL ACID LIPASE THERAPY FOR NAFLD AND RELATED DISEASES CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2007-03-15 WO claimed
US-20060198890-A1 Durable film coating compositions having sustained slow-release capability, and methods of use therefor KEYSTONE INDUSTRIES 2006-09-07 US claimed
WO-2005023305-A2 MODULATING CELL ACTIVITY BY USING AN AGENT THAT REDUCES THE LEVEL OF CHOLESTEROL WITHIN A CELL INPHARMATICA LIMITED (GB) 2005-03-17 WO claimed
US-20030175347-A1 Durable film coating compositions having sustained slow-release capability, and methods of use therefor KEYSTONE INDUSTRIES 2003-09-18 US claimed
US-6306203-B1 FOR USE IN INK JET PRINTING, INCLUDING PIEZOELECTRIC INK JET PRINTING AND ACOUSTIC INK JET PRINTING XEROX CORPORATION 2001-10-23 US claimed
WO-2001000684-A1 LIQUID OLIGOMERS CONTAINING UNSATURATION ASHLAND INC. (US) 2001-01-04 WO claimed
US-5403426-A Surface treatment HERCULES INCORPORATED (US) 1995-04-04 US claimed
CN-1073457-A Produce the method for plasticised polyvinyl alcohol and be used to prepare the thermoplastic compounds of starch-based, biodegradable NOVAMONT SPA (IT) 1993-06-23 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249692-A1 INHIBITORS OF CRYSTALLIZATION IN A SOLID DISPERSION GYS2, CSPP1, RCC1 ALDH1A1 3513/4885LMNA 2435/4885HSD17B10 998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.